30,000 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by LMR Partners LLP

LMR Partners LLP purchased a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $400,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $15,511,000. Affinity Asset Advisors LLC acquired a new position in Perspective Therapeutics in the first quarter worth $6,069,000. Vanguard Group Inc. grew its holdings in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. Nicholson Wealth Management Group LLC acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at $21,390,000. Finally, Hills Bank & Trust Co acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at $13,722,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Stock Down 2.6 %

Shares of Perspective Therapeutics stock opened at $6.78 on Wednesday. The business’s fifty day moving average is $12.37. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. As a group, equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on CATX shares. Bank of America assumed coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of Perspective Therapeutics in a report on Thursday, October 24th. UBS Group initiated coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective on the stock. Oppenheimer reissued an “outperform” rating and issued a $22.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 11th. Finally, Royal Bank of Canada cut their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Perspective Therapeutics currently has an average rating of “Buy” and a consensus price target of $21.57.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.